Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Apr;84(7):975–981. doi: 10.1054/bjoc.2001.1704

Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study

A Zeleniuch-Jacquotte 1,2, A Akhmedkhanov 1,3, I Kato 4, K L Koenig 1,2, R E Shore 1,2, M Y Kim 1,2, M Levitz 3, K R Mittal 5, U Raju 3, S Banerjee 3, P Toniolo 1,2,3
PMCID: PMC2363831  PMID: 11286480

Abstract

We assessed the association of postmenopausal serum levels of oestrogens and sex hormone-binding globulin (SHBG) with endometrial cancer risk in a case–control study nested within the NYU Women's Health Study cohort. Among 7054 women postmenopausal at enrolment, 57 cases of endometrial cancer were diagnosed a median of 5.5 years after blood donation. Each case was compared to 4 controls matched on age, menopausal status at enrolment, and serum storage duration. Endometrial cancer risk increased with higher levels of oestradiol (odds ratio = 2.4 in highest vs lowest tertile, P for trend = 0.02), percent free oestradiol (OR = 3.5, P< 0.001), and oestrone (OR = 3.9, P< 0.001). Risk decreased with higher levels of percent SHBG-bound oestradiol (OR = 0.43, P = 0.03) and SHBG (OR = 0.39, P = 0.01). Trends remained in the same directions after adjusting for height and body mass index. A positive association of body mass index with risk was substantially reduced after adjusting for oestrone level. Our results indicate that risk of endometrial cancer increases with increasing postmenopausal oestrogen levels but do not provide strong support for a role of body mass index independent of its effect on oestrogen levels. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: endometrial cancer, oestrogen, oestradiol, SHBG, nested case–control study, body mass index

Full Text

The Full Text of this article is available as a PDF (70.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham G. E., Tulchinsky D., Korenman S. G. Chromatographic purification of estradiol-17 for use in radio-ligand assay. Biochem Med. 1970 Apr;3(5):365–368. doi: 10.1016/0006-2944(70)90002-5. [DOI] [PubMed] [Google Scholar]
  2. Aleem F. A., Moukhtar M. A., Hung H. C., Romney S. L. Plasma estrogen in patients with endometrial hyperplasia and carcinoma. Cancer. 1976 Nov;38(5):2101–2104. doi: 10.1002/1097-0142(197611)38:5<2101::aid-cncr2820380537>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  3. Armstrong B. G., Whittemore A. S., Howe G. R. Analysis of case-control data with covariate measurement error: application to diet and colon cancer. Stat Med. 1989 Sep;8(9):1151–1166. doi: 10.1002/sim.4780080916. [DOI] [PubMed] [Google Scholar]
  4. Austin H., Austin J. M., Jr, Partridge E. E., Hatch K. D., Shingleton H. M. Endometrial cancer, obesity, and body fat distribution. Cancer Res. 1991 Jan 15;51(2):568–572. [PubMed] [Google Scholar]
  5. Benjamin F., Deutsch S. Plasma levels of fractionated estrogens and pituitary hormones in endometrial carcinoma. Am J Obstet Gynecol. 1976 Nov 15;126(6):638–647. doi: 10.1016/0002-9378(76)90511-1. [DOI] [PubMed] [Google Scholar]
  6. Bremond A. G., Claustrat B., Rudigoz R. C., Seffert P., Corniau J. Estradiol, androstenedione, testosterone, and dehydroepiandrosterone sulfate in the ovarian and peripheral blood of postmenopausal patients with and without endometrial cancer. Gynecol Oncol. 1982 Aug;14(1):119–124. doi: 10.1016/0090-8258(82)90058-0. [DOI] [PubMed] [Google Scholar]
  7. Davidson B. J., Gambone J. C., Lagasse L. D., Castaldo T. W., Hammond G. L., Siiteri P. K., Judd H. L. Free estradiol in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab. 1981 Mar;52(3):404–408. doi: 10.1210/jcem-52-3-404. [DOI] [PubMed] [Google Scholar]
  8. Derby C. A., Hume A. L., Barbour M. M., McPhillips J. B., Lasater T. M., Carleton R. A. Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. Am J Epidemiol. 1993 May 15;137(10):1125–1135. doi: 10.1093/oxfordjournals.aje.a116616. [DOI] [PubMed] [Google Scholar]
  9. Ferenczy A., Bertrand G., Gelfand M. M. Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol. 1979 Apr 15;133(8):859–867. doi: 10.1016/0002-9378(79)90302-8. [DOI] [PubMed] [Google Scholar]
  10. Gimes G., Szarvas Z., Siklósi G. Endocrine factors in the etiology of endometrial carcinoma. Neoplasma. 1986;33(3):393–397. [PubMed] [Google Scholar]
  11. Hankinson S. E., Manson J. E., Spiegelman D., Willett W. C., Longcope C., Speizer F. E. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):649–654. [PubMed] [Google Scholar]
  12. Henderson B. E., Ross R. K., Pike M. C., Casagrande J. T. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982 Aug;42(8):3232–3239. [PubMed] [Google Scholar]
  13. Jasonni V. M., Bulletti C., Franceschetti F., Bonavia M., Bolelli G., Ciotti P., Flamigni C. Estrone sulphate plasma levels in postmenopausal women with and without endometrial cancer. Cancer. 1984 Jun 15;53(12):2698–2700. doi: 10.1002/1097-0142(19840615)53:12<2698::aid-cncr2820531223>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  14. Judd H. L., Davidson B. J., Frumar A. M., Shamonki I. M., Lagasse L. D., Ballon S. C. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol. 1980 Apr 1;136(7):859–871. doi: 10.1016/0002-9378(80)91043-1. [DOI] [PubMed] [Google Scholar]
  15. Judd H. L., Lucas W. E., Yen S. S. Serum 17 beta-estradiol and estrone levels in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab. 1976 Aug;43(2):272–278. doi: 10.1210/jcem-43-2-272. [DOI] [PubMed] [Google Scholar]
  16. Kato I., Toniolo P., Koenig K. L., Kahn A., Schymura M., Zeleniuch-Jacquotte A. Comparison of active and cancer registry-based follow-up for breast cancer in a prospective cohort study. Am J Epidemiol. 1999 Feb 15;149(4):372–378. doi: 10.1093/oxfordjournals.aje.a009823. [DOI] [PubMed] [Google Scholar]
  17. Key T. J., Pike M. C. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988 Feb;57(2):205–212. doi: 10.1038/bjc.1988.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lubin J. H., Gail M. H. Biased selection of controls for case-control analyses of cohort studies. Biometrics. 1984 Mar;40(1):63–75. [PubMed] [Google Scholar]
  19. Michels K. B., Greenland S., Rosner B. A. Does body mass index adequately capture the relation of body composition and body size to health outcomes? Am J Epidemiol. 1998 Jan 15;147(2):167–172. doi: 10.1093/oxfordjournals.aje.a009430. [DOI] [PubMed] [Google Scholar]
  20. Nisker J. A., Hammond G. L., Davidson B. J., Frumar A. M., Takaki N. K., Judd H. L., Siiteri P. K. Serum sex hormone-binding globulin capacity and the percentage of free estradiol in postmenopausal women with and without endometrial carcinoma. A new biochemical basis for the association between obesity and endometrial carcinoma. Am J Obstet Gynecol. 1980 Nov 15;138(6):637–642. doi: 10.1016/0002-9378(80)90080-0. [DOI] [PubMed] [Google Scholar]
  21. Nyholm H. C., Nielsen A. L., Lyndrup J., Dreisler A., Hagen C., Haug E. Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol. 1993 Dec;100(12):1115–1119. doi: 10.1111/j.1471-0528.1993.tb15176.x. [DOI] [PubMed] [Google Scholar]
  22. Pettersson B., Bergström R., Johansson E. D. Serum estrogens and androgens in women with endometrial carcinoma. Gynecol Oncol. 1986 Oct;25(2):223–233. doi: 10.1016/0090-8258(86)90103-4. [DOI] [PubMed] [Google Scholar]
  23. Pike M. C., Peters R. K., Cozen W., Probst-Hensch N. M., Felix J. C., Wan P. C., Mack T. M. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997 Aug 6;89(15):1110–1116. doi: 10.1093/jnci/89.15.1110. [DOI] [PubMed] [Google Scholar]
  24. Potischman N., Gail M. H., Troisi R., Wacholder S., Hoover R. N. Measurement error does not explain the persistence of a body mass index association with endometrial cancer after adjustment for endogenous hormones. Epidemiology. 1999 Jan;10(1):76–79. [PubMed] [Google Scholar]
  25. Potischman N., Hoover R. N., Brinton L. A., Siiteri P., Dorgan J. F., Swanson C. A., Berman M. L., Mortel R., Twiggs L. B., Barrett R. J. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996 Aug 21;88(16):1127–1135. doi: 10.1093/jnci/88.16.1127. [DOI] [PubMed] [Google Scholar]
  26. Sherman M. E. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000 Mar;13(3):295–308. doi: 10.1038/modpathol.3880051. [DOI] [PubMed] [Google Scholar]
  27. Siiteri P. K. Steroid hormones and endometrial cancer. Cancer Res. 1978 Nov;38(11 Pt 2):4360–4366. [PubMed] [Google Scholar]
  28. Sonnenschein E. G., Kim M. Y., Pasternack B. S., Toniolo P. G. Sources of variability in waist and hip measurements in middle-aged women. Am J Epidemiol. 1993 Sep 1;138(5):301–309. doi: 10.1093/oxfordjournals.aje.a116859. [DOI] [PubMed] [Google Scholar]
  29. Toniolo P. G., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K. L., Shore R. E., Strax P., Pasternack B. S. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 1995 Feb 1;87(3):190–197. doi: 10.1093/jnci/87.3.190. [DOI] [PubMed] [Google Scholar]
  30. Toniolo P. G., Pasternack B. S., Shore R. E., Sonnenschein E., Koenig K. L., Rosenberg C., Strax P., Strax S. Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat. 1991 May;18 (Suppl 1):S23–S26. doi: 10.1007/BF02633522. [DOI] [PubMed] [Google Scholar]
  31. Toniolo P., Koenig K. L., Pasternack B. S., Banerjee S., Rosenberg C., Shore R. E., Strax P., Levitz M. Reliability of measurements of total, protein-bound, and unbound estradiol in serum. Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):47–50. [PubMed] [Google Scholar]
  32. Weiderpass E., Adami H. O., Baron J. A., Magnusson C., Bergström R., Lindgren A., Correia N., Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999 Jul 7;91(13):1131–1137. doi: 10.1093/jnci/91.13.1131. [DOI] [PubMed] [Google Scholar]
  33. von Holst T., Klinga K., Runnebaum B. Hormone levels in healthy post-menopausal women and in women with post-menopausal bleeding with or without endometrial carcinoma. Maturitas. 1981 Dec;3(3-4):315–320. doi: 10.1016/0378-5122(81)90040-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES